瑞康医药
(002589)
| 流通市值：45.34亿 | | | 总市值：49.96亿 |
| 流通股本：13.66亿 | | | 总股本：15.05亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,056,194,532.51 | 4,031,665,203.8 | 2,018,758,765.18 | 8,034,367,997.33 |
| 营业收入 | 6,056,194,532.51 | 4,031,665,203.8 | 2,018,758,765.18 | 8,034,367,997.33 |
| 二、营业总成本 | 5,997,705,441.86 | 3,997,336,554.85 | 2,023,237,316.54 | 8,240,564,392.56 |
| 营业成本 | 5,265,530,452.49 | 3,525,841,738.41 | 1,775,624,876.88 | 7,207,335,794.48 |
| 税金及附加 | 26,800,898.1 | 17,069,856.86 | 7,351,008.64 | 45,716,524.02 |
| 销售费用 | 275,357,168.85 | 190,452,112.1 | 89,882,828.94 | 431,996,741.55 |
| 管理费用 | 293,252,275.18 | 175,152,600.54 | 91,616,188.4 | 408,259,565.59 |
| 研发费用 | 7,566,022.65 | 5,479,545.12 | 3,103,612.68 | 14,615,574.1 |
| 财务费用 | 129,198,624.59 | 83,340,701.82 | 55,658,801 | 132,640,192.82 |
| 其中:利息费用 | 166,706,929.51 | 108,093,221.28 | 67,541,143.52 | 303,702,002.77 |
| 其中:利息收入 | 59,335,714.37 | 44,112,222.96 | 29,091,508.25 | 190,709,173.68 |
| 加:公允价值变动收益 | 12,464,457.63 | - | - | -228,896,122.98 |
| 加:投资收益 | 29,014,904.55 | 32,150,163.64 | 5,003,521.62 | 408,821,559.9 |
| 资产处置收益 | -6,467,871.93 | -5,899,298.78 | -5,950,298.85 | -7,924,504.83 |
| 资产减值损失(新) | 708,089.19 | 708,089.19 | 0 | -33,485,159.48 |
| 信用减值损失(新) | -42,741,474.43 | -19,570,124.7 | 31,772,247.1 | -67,735,303.51 |
| 其他收益 | 1,869,258.5 | 1,371,992.65 | 36,631.62 | 8,780,489.74 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 53,336,454.16 | 43,089,470.95 | 26,383,550.13 | -126,635,436.39 |
| 加:营业外收入 | 1,850,298.04 | 982,757.83 | 262,131.13 | 2,932,969.92 |
| 减:营业外支出 | 8,072,922.87 | 3,886,179.09 | 2,234,859.15 | 11,715,249.83 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 47,113,829.33 | 40,186,049.69 | 24,410,822.11 | -135,417,716.3 |
| 减:所得税费用 | -5,135,191.98 | -365,935.21 | 5,839,723.31 | -167,388,950.92 |
| 六、净利润 | 52,249,021.31 | 40,551,984.9 | 18,571,098.8 | 31,971,234.62 |
| 持续经营净利润 | 52,249,021.31 | 40,551,984.9 | 18,571,098.8 | 31,971,234.62 |
| 归属于母公司股东的净利润 | 38,806,313.59 | 31,025,324.74 | 15,168,972.69 | 20,317,689.35 |
| 少数股东损益 | 13,442,707.72 | 9,526,660.16 | 3,402,126.11 | 11,653,545.27 |
| (一)基本每股收益 | 0.03 | 0.02 | 0.01 | 0.01 |
| (二)稀释每股收益 | 0.03 | 0.02 | 0.01 | 0.01 |
| 九、综合收益总额 | 52,249,021.31 | 40,551,984.9 | 18,571,098.8 | 31,971,234.62 |
| 归属于母公司股东的综合收益总额 | 38,806,313.59 | 31,025,324.74 | 15,168,972.69 | 20,317,689.35 |
| 归属于少数股东的综合收益总额 | 13,442,707.72 | 9,526,660.16 | 3,402,126.11 | 11,653,545.27 |
| 公告日期 | 2024-10-31 | 2024-08-27 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |